Location: Solmed Polyclinic (Zagreb)
Study Drug: Patients will be treated with either standard biologic therapy (okrelizumab) or a biosimilar of okrelizumab.
Main Inclusion Criteria: Patients over 18 years old with an official diagnosis of relapsing-remitting multiple sclerosis, who have not been previously treated with the biologic therapy okrelizumab and, despite existing therapy, have symptoms of active disease.
Status: Patient enrollment starting soon
Start of patient enrollment: April 2024.
